Family planning advocates can help ensure that a country’s policies and funding promote access to DMPA-SC and self-injection along with other contraceptive options so women can make an informed and voluntary choice.
Decision-makers need to advance relevant approvals and policies to introduce or scale up DMPA-SC and self-injection, alongside integration in guidelines, training materials, logistics management systems, and health monitoring and information systems. Advocacy tools and approaches are available here to guide development of an advocacy strategy and action plan that speaks to your country context. Materials are also available to create compelling and accurate messaging and public outreach.
This brief summarizes recent evidence from African countries on the costs and cost-effectiveness of DMPA-SC. Key findings include that DMPA-SC may help reduce service delivery costs by catalyzing expansion of channels closest to women and that self-injected DMPA-SC is cost-saving as compared to clinic-administered DMPA-IM when accounting for costs to women and health systems.
This brief offers concise, evidence-based information to help answer common questions and dispel myths about injectable contraception. Myths are not stated directly because repeating a myth may reinforce it in people’s minds.
This customizable slide deck provides a brief description of DMPA-SC and its benefits; an overview of evidence on how the product expands access through multiple delivery channels; and illustrative policy and advocacy gaps and recommendations for country decision-makers.
A customizable document that provides a brief description of DMPA-SC; an overview of evidence on how the product expands access through multiple delivery channels; and policy and advocacy recommendations for country decision-makers tied to the country’s stage of access.
Describes key evidence-building efforts, advocacy actions, and policy changes in Uganda brought about by key partners to increase access to injectable contraception, including DMPA-SC. You can draw on lessons learned from Uganda to inform your policy goals and advocacy strategy for increasing method choice and access with DMPA-SC in your country.
Summarizes important takeaways for advocates from the latest guidance released by the World Health Organization on hormonal contraception, including DMPA injectables, and HIV for women at high risk of HIV.
The working meeting on “The Future of DMPA-SC: Expanding access and options in 2019” was held in November 2018 as a pre-meeting before the International Conference on Family Planning (ICFP) in Kigali, Rwanda was intended to bring together colleagues and partners working to introduce and scale-up subcutaneous DMPA (DMPA-SC or SC) in 14 countries to exchange challenges, successes, and lessons learned—and to plan together how they can continue to expand women’s access and options with DMPA-SC.